|drug3471||Thrombin Generation Assay (TGA) Wiki||0.71|
|drug3473||Thrombomodulin Modified Thrombin Generation Assay (TGA-TM) Wiki||0.71|
|D004211||Disseminated Intravascular Coagulation NIH||0.35|
|D020141||Hemostatic Disorders NIH||0.19|
There are 2 clinical trials
In the context of the COVID19 pandemic and containment, chest CT is currently frequently performed on admission, looking for suggestive signs and basic abnormalities of COVID19 compatible viral pneumonitis pending confirmation of identification of viral RNA by reverse-transcription polymerase chain reaction(PCR), with a reported sensitivity of 56-88% in the first few days, slightly higher than PCR (60%) (1). Nevertheless, currently established radiological abnormalities are not specific for COVID19 and the specificity of the chest CT is ~25% when PCR is used as a reference (1). Deconfinement and its consequences will complicate the triage of COVID patients and the role of the scanner, with the expected impact of a decrease in the prevalence of infection in the emergency department and an increase in the number of "all-round" patients, including patients with non-COVID viral infiltrates or pneumopathies. In addition, there are currently no imaging criteria to complement the clinical and biological data that can predict the progression of lung disease from the initial data.
Description: The diagnostoc of COVID disease is composite of: CT features wich will include presence/location/laterality of morphological CT abonormal densities (ground glass opacities, consolidations, reticulations), pulmonary vessels size, distribution and abnormalities, local / global CT-ventilation index (CT-VI) severity, radiomic features (shape features, 1st-order and 2nd order statistics) Analysis of CT-Scan results.Measure: diagnostic of COVID disease composite Time: On admission to the hospital
The most common thorax Computed tomography (CT) findings are multifocal ground-glass opacities and peripheral consolidation in patients with COVID-19. Septal thickening, bronchiectasis, pleural thickening, and subpleural involvement may also be observed. Although these findings are not specific to COVID-19, the severity of pulmonary involvement is expected to be correlated with thorax CT findings.
Description: Whether Thorax CT findings predict invasive mechanical ventilation requirement of covid-19 patientsMeasure: Invasive respiratory support in patients with COVID-19 Time: 120 days
Description: Whether Thorax CT findings predict mortality of covid-19 patientsMeasure: Mortality in patients with COVID-19 Time: 120 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports